Physician profile
Amberly D Wright
NPI 1356968150
$2,123.16
in general payments reported to CMS, 2019-2025
19 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $391 · 2023: $30.63 · 2024: $677 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $326.72 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $304.71 | 2021-2022 | |
| Medtronic, INC. | $222.08 | 2021-2024 | Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $212.97 | 2024-2025 | Evoke |
| Biodelivery Sciences International, INC. | $157.36 | 2021 | |
| Boston Scientific Corporation | $145.98 | 2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $140.40 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $121.86 | 2025 | Iovera |
| Redhill Biopharma INC. | $102.04 | 2021 | |
| Abbvie INC. | $81.21 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $68.44 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.61 | 2023-2024 | Relistor |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Abiomed | $36.17 | 2024 | Impella |
| Ucb, INC. | $31.51 | 2025 | Cimzia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.42 | 2025 | Zepbound |
| Amgen INC. | $19.28 | 2021 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Valinor Pharma, LLC | $13.71 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amberly Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.